SCCPDH (saccharopine dehydrogenase-like oxidoreductase) is a putative oxidoreductase localized to multiple cellular compartments including the nucleus, mitochondrion, and lipid droplets 1. While its precise enzymatic function remains uncharacterized, SCCPDH appears to play a role in amino acid metabolism regulation 1. Clinically, SCCPDH has emerged as a relevant biomarker in two distinct disease contexts. In preeclampsia, SCCPDH was identified as a hub gene with high diagnostic value (AUC: 0.88) and significantly altered expression levels compared to healthy controls, suggesting potential utility in early disease detection 2. In Parkinson disease models, SCCPDH expression was downregulated following intranigral cell transplantation, implicating it in lipid metabolism and dopamine vesicle recycling pathways critical for nigrostriatal reconstruction 3. Pharmacologically, SCCPDH serves as an off-target for the cystic fibrosis corrector VX-445 1. VX-445 binding to SCCPDH demonstrates inhibitory activity and dysregulates amino acid metabolism 1, potentially explaining observed psychological side effects in treated patients. SCCPDH also shows binding affinity to AXL kinase inhibitors during off-target screening 4, indicating broader drug-target interactions requiring consideration during inhibitor development.